New Glaucoma Care Restriction: IOP Targets and Treatment Access

Glaucoma encompasses a group of optic neuropathies characterised by progressive retinal ganglion cell death and corresponding visual field loss. Elevated intraocular pressure (IOP) is the primary modifiable risk factor, and its reduction remains the cornerstone of therapeutic intervention. The goal of treatment is to lower IOP to a level that prevents further optic nerve damage, often referred to as the 'target IOP'. This target is individualised based on factors such as baseline IOP, severity of optic nerve damage, visual field status, and patient age. For many patients with primary open-angle glaucoma (POAG) or ocular hypertension (OHT), the initial target IOP reduction is typically 25-30% from baseline. The European Glaucoma Society guidelines, for instance, recommend an initial IOP reduction of at least 20% for early to moderate glaucoma, with more aggressive targets for advanced disease.¹

Pharmacological therapy for glaucoma primarily involves topical eye drops that either decrease aqueous humour production or increase aqueous humour outflow. Prostaglandin analogues (PGAs), such as latanoprost, travoprost, bimatoprost, and tafluprost, are widely recognised as the most effective and generally well-tolerated first-line agents for reducing IOP. Their mechanism of action involves increasing uveoscleral outflow, leading to sustained IOP reduction over a 24-hour period. Clinical trials have consistently demonstrated their efficacy. For example, a meta-analysis comparing various PGAs reported mean IOP reductions ranging from 25% to 33% from baseline, with some studies showing reductions of up to 35% in specific cohorts.² The once-daily dosing regimen of PGAs also contributes to better patient adherence compared to medications requiring multiple daily applications, a critical factor in chronic disease management.³

The recent policy change restricts the first-line prescribing of certain prostaglandin analogues, specifically those that are not generic latanoprost. This decision mandates that clinicians initiate treatment with generic latanoprost before considering other PGA options or alternative drug classes. While generic latanoprost is an effective agent, this restriction overlooks the nuanced differences in efficacy, tolerability, and patient response observed among the various PGAs. For instance, travoprost has demonstrated a slightly greater IOP reduction in some comparative studies, particularly in patients with higher baseline IOPs. A randomised controlled trial comparing travoprost 0.004% with latanoprost 0.005% found that travoprost achieved a mean diurnal IOP reduction of 8.1 mmHg from a baseline of 25.3 mmHg, compared to 7.2 mmHg for latanoprost from a baseline of 25.1 mmHg, representing a statistically significant difference (p=0.004).⁴ Similarly, bimatoprost 0.03% has been shown to provide superior IOP lowering compared to latanoprost 0.005% in several head-to-head trials, with one study reporting a mean IOP reduction of 8.3 mmHg for bimatoprost versus 7.0 mmHg for latanoprost (p<0.001).⁵ These differences, while seemingly small, can be clinically meaningful for patients requiring aggressive IOP lowering to prevent disease progression.

Furthermore, patient tolerability and response to specific PGAs can vary. Ocular surface disease, including dry eye and conjunctival hyperaemia, is a common comorbidity in glaucoma patients and can be exacerbated by topical medications. While PGAs are generally well-tolerated, individual patients may experience different adverse effect profiles with different agents. For example, some patients may tolerate one PGA better than another due to variations in preservative content or specific molecular structure. The restriction to a single generic option as first-line therapy removes the clinician's ability to select the most appropriate PGA based on individual patient characteristics, potential for adverse effects, and the specific IOP target required. This could lead to a delay in achieving target IOP, necessitating earlier escalation to combination therapy or surgical intervention, which carry their own risks and costs.⁶

Implications for Clinical Practice and Patient Outcomes

The immediate consequence of this policy is that clinicians must now navigate a more rigid treatment pathway. For patients who may not achieve their target IOP with generic latanoprost, or who experience intolerable side effects, a switch to another PGA or a different class of medication will be required. This sequential approach introduces additional clinic visits, potential delays in optimal IOP control, and increased patient anxiety. Each medication switch requires a washout period or careful monitoring to assess the new agent's efficacy, prolonging the time until stable IOP is achieved. This is particularly concerning for patients with advanced glaucoma or rapidly progressing disease, where timely and effective IOP reduction is paramount to preserving vision.⁷

The long-term implications for patient outcomes are also a concern. Suboptimal IOP control, even for short periods, can contribute to further optic nerve damage and visual field loss. A study investigating the impact of IOP fluctuation on glaucoma progression found that greater variability in IOP was associated with a higher risk of visual field deterioration, independent of mean IOP.⁸ By limiting initial treatment choices, the policy may inadvertently increase the likelihood of IOP fluctuations or delays in achieving stable target IOP, potentially accelerating disease progression in a subset of patients. Moreover, the restriction may lead to increased prescribing of combination therapies earlier in the treatment algorithm, as clinicians seek to achieve target IOP when monotherapy with generic latanoprost proves insufficient. While combination therapies are effective, they often involve higher costs, increased complexity of dosing regimens, and a greater likelihood of adverse effects, all of which can negatively impact patient adherence.⁹

From an economic perspective, the rationale behind such a policy is often cost containment. Generic latanoprost is typically less expensive than branded PGAs or other generic PGAs. However, the potential for increased healthcare costs due to more frequent clinic visits, medication switches, earlier use of more expensive combination therapies, or even the long-term costs associated with managing advanced glaucoma (e.g., low vision services, surgical interventions) must be considered. A comprehensive cost-effectiveness analysis would need to account for these downstream effects to determine the true economic impact of such a restrictive policy. The initial cost saving on medication may be offset by increased costs elsewhere in the patient care pathway.¹⁰

The policy also raises questions about the balance between cost-effectiveness and clinical autonomy. Clinicians, based on their expertise and understanding of individual patient needs, are best positioned to select the most appropriate initial therapy. Restricting this choice to a single generic option, without clear clinical justification based on superior efficacy or safety of that specific agent across all patient populations, undermines evidence-based medicine and personalised care. While generic medications play a vital role in healthcare affordability, blanket restrictions that do not account for individual patient variability or the subtle but clinically relevant differences between agents within a drug class can have unintended negative consequences. The availability of multiple PGA options allows for tailoring treatment to optimise both efficacy and tolerability, thereby maximising the chances of long-term adherence and successful IOP control.¹¹

In conclusion, while generic latanoprost is an effective first-line agent for glaucoma, the new policy restricting initial PGA choice warrants a closer look. The potential for delayed target IOP attainment, increased patient burden due to medication switches, and the erosion of clinical autonomy in selecting the most appropriate initial therapy are significant concerns. Future evaluations of this policy should consider not only the immediate cost savings but also the broader impact on patient outcomes, healthcare resource utilisation, and the quality of glaucoma care.